Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

By Hirst C.   Pace A.   Pickersgill T.   Jones R.   McLean B.   Zajicek J.   Scolding N.   Robertson N.  

Journal of Neurology, Vol. 255, Iss. 2, 2008-02 ,pp. : 231-238

Springer Publishing Company

Access to resources Recommend Favorite

Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

By Gold Ralf   Comi Giancarlo   Palace Jacqueline   Siever Arno   Gottschalk Rebecca   Bijarnia Mahendra   Rosenstiel Philipp   Tomic Davorka   Kappos Ludwig  

Journal of Neurology, Vol. 261, Iss. 4, 2014-04 ,pp. : 850-850

Springer Publishing Company

Access to resources Recommend Favorite

Development of laquinimod for relapsing––remitting multiple sclerosis

By Jeffery Douglas R  

Future Neurology, Vol. 3, Iss. 6, 2008-11 ,pp. : 641-648

Future Medicine

Access to resources Recommend Favorite

Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis

By Rejdak K.   Petzold A.   Kocki T.   Kurzepa J.   Grieb P.   Turski W. A.   Stelmasiak Z.  

Journal of Neural Transmission, Vol. 114, Iss. 8, 2007-08 ,pp. : 1011-1015

Springer Publishing Company

Access to resources Recommend Favorite

Differential response to treatment of relapsing–remitting multiple sclerosis with IFN-&bgr;: is there a dichotomy into T-helper-1 and -17 driven disease?

By Weissert Robert  

Future Neurology, Vol. 5, Iss. 4, 2010-07 ,pp. : 481-484

Future Medicine

Access to resources Recommend Favorite